We examined the antitumor effect of locally secreted interleukin (IL)-12 or IL-15 on human pancreatic cancer cells (AsPC-1). We subcutaneously inoculated AsPC-1 cells retrovirally transduced with IL-12 or IL-15 cDNA into nude mice. Tumors derived from these cells showed retarded growth compared with those from wild-type (wt) cells. Nude mice inoculated intraperitoneally with the cytokine producers survived longer than those injected with wt cells. These cytokine producers were also tested for their tumor growth in severe combined immunodeficient mice. The tumor growth of IL-12 producers was similarly suppressed as found in nude mice, but the average tumor volumes of IL-15 producers were not statistically different from those of wt tumors. In nude mice that were administered anti-asialo GM 1 antibody before the inoculation of the tumor cells, growth retardation of tumors of IL-12 producers remained the same as in untreated animals, but that of IL-15 producers was markedly reduced. Immunohistochemical analysis revealed that CD11b ϩ cells migrated into the tumors of cytokine producers and that the number of CD31 ϩ endothelial cells within the tumors was not different between IL-12 producers and wt cells. Taken together with other data, it is possible that granulocytes are candidate cells for the IL-12-mediated antitumor effect, and that natural killer cells and ␥␦ T cells are involved in the IL-15-induced antitumor effect. We did not observe synergistic effects of these cytokines to suppress subcutaneous tumors.
T he prognosis of pancreatic cancer remains poor, 1, 2 despite recent progress in diagnostic modalities and therapeutic procedures. New strategies other than presently used therapies are required. Immunogene therapy would be one of the candidate procedures because its efficacy has been demonstrated in various types of experimental models, and the possibility of its clinical application is being tested. 3, 4 However, there are few reports concerning immunogene therapy for pancreatic cancer. [5] [6] [7] We have shown the effect of human pancreatic cancer cells (AsPC-1) transduced with granulocytemacrophage colony-stimulating factor, 8 interleukin-2 (IL-2), or IL-4 9 cDNA on in vivo tumorigenicity. In this study, we investigated whether the IL-12 or IL-15 secreted from AsPC-1 cells could produce a suppressive effect on their tumor growth.
T helper (Th) cells, which play critical roles in the initiation of immune reactions, can be divided into two subsets (Th1 and Th2 cells) based on their ability to produce discrete patterns of cytokines. 10 Th1 cells, which secrete IL-2 and/or interferon-␥ (IFN-␥) but not IL-4 or IL-5, are important for cell-mediated immunity, whereas Th2 cells, which secrete IL-4 and/or IL-5 but not IL-2 or IFN-␥, are primarily responsible for humoral immunity. 10 Human neoplastic diseases are frequently associated with an elevated production of Th2-type cytokines and/or a reduced production of Th1-type cytokines. 11 This disordered secretion profile of cytokines may be one of the reasons why cancer cells can escape from the attack of host immune systems. It is thereby worthwhile to test the augmented production of Th1-type cytokines for enhanced antitumor responses. 12 IL-12 can generate Th1 cells from naive T cells. 13 It also directly stimulates the production of IFN-␥ from T and natural killer (NK) cells 14, 15 and augments the cytolytic activity of cytotoxic T cells, 16 lymphokineactivated killer cells, 17 and NK cells. 16 In addition, IL-12 can inhibit neovascularization in growing tumors. 18 Clin-ical trials using either recombinant IL-12 (rIL-12) or an IL-12 gene expression system have started for certain kinds of cancers, including melanoma and breast cancer. 19 -22 IL-15 is a recently discovered cytokine. 23, 24 Because IL-15 requires the use of ␤-and ␥-chains of the IL-2 receptor (IL-2R) for its binding and signaling, 25 IL-15 is suggested to possess stimulatory effects on activated T, B, and NK cells [25] [26] [27] [28] [29] that are similar to those of IL-2. However, whereas IL-2 is predominantly secreted from activated T cells, IL-15 is produced by a wide variety of cells and tissues. 23 Moreover, IL-15R has a specific subunit (IL-15R␣). 30 IL-15 is thus expected to exhibit antitumor effects that may be different from those of IL-2.
Because IL-12 and IL-15 are possible candidates for cancer gene therapy, we explore in this paper whether these cytokines can induce an antitumor effect against human pancreatic cancer cells in immunodeficient mice.
MATERIALS AND METHODS

Mice and cells
Six-week-old female BALB/c nu/nu and BALB/c scid/scid (severe combined immunodeficient (SCID)) mice were purchased from Japan SLC (Hamamatsu, Japan) and Clea Japan (Tokyo, Japan), respectively. AsPC-1, ⌿2 (ecotropic packaging cells), and PA317 (amphotropic packaging cells) cells were obtained from the American Type Culture Collection (Manassas, Va). AsPC-1 cells were cultured in RPMI 1640 medium supplemented with 10% fetal calf sera, and ⌿2 and PA317 cells were cultured in Dulbecco's modified Eagle's medium with 10% fetal calf sera.
Isolation of murine cytokine genes
The reverse transcription-based polymerase chain reaction method was used to clone IL-12 and IL-15 cDNAs. Poly(A ϩ ) mRNAs of IL-12 and IL-15 were extracted from Zysorbinestimulated C57BL/6 and lipopolysaccharide-stimulated BALB/c mouse spleen cells, respectively. First-strand cDNAs were synthesized and amplified with their respective primers. For IL-12 p35 cDNA, 5Ј-GGAATTCGCCGGCTATCCAGA-CAATTATA-3Ј (as a 5Ј primer) and 5Ј-GGGATCCTGTTTC-CTATCTGTGTGAGGAG-3Ј (as a 3Ј primer) were used. For IL-12 p40 cDNA, 5Ј-GGAATTCGCACATCAGACCAG-GCAGCTCG-3Ј (as a 5Ј primer) and 5Ј-GGGATCCTC-CAACGTTGCATCCTAGGATC-3Ј (as a 3Ј primer) were used. For IL-15 cDNA, 5Ј-ATTACTCGAGCCATAGC-CAGCTCATCTTCAAC-3Ј (as a 5Ј primer) and 5Ј-ACT-ACTCGAGAGCAGGTGGAGGTACCTTAATAAC-3Ј (as a 3Ј primer) were used. Amplification consisting of 30 cycles was performed according to the manufacturer's recommendations (Perkin-Elmer Cetus, Norwalk, Conn). The cycle profile for IL-12 cDNA was 1 minute at 93°C for denaturation, 1 minute at 65°C for primer annealing, and 2 minutes at 72°C for primer extension. The profile for IL-15 cDNA was 1 minute at 94°C for denaturation, 1 minute at 60°C for primer annealing, and 2 minutes at 72°C for primer extension. The sequences of the obtained cDNAs were confirmed to match the published sequences. 31, 32 Establishment of transduced cells with cytokine gene 33 was used to link p35 and p40 cDNA. The vector DNA with the corresponding cytokine gene was transfected into ⌿2 cells with Lipofectin reagent (Life Technologies, Gaithersburg, Md) and, after the drug selection with Geneticin (Life Technologies), cell-free culture supernatants containing retroviral particles were collected. PA317 cells were infected with the retrovirus in the presence of 8 g/mL polybrene (Aldrich, Milwaukee, Wis). After Geneticin-mediated selection of transduced cells, the clone that produced the largest amount of corresponding mRNA was selected. AsPC-1 cells were infected with respective retroviruses in the same way as described above. The amounts of secreted IL-12 or IL-15 were quantified with an enzyme-linked immunosorbent assay kit (Biosource, Camarillo, Calif) or with an immunosorbent assay using anti-IL-15 monoclonal antibodies (mAbs) (PharMingen, San Diego, Calif) as described in the manufacturer's instructions. We could not, however, determine the absolute amount of secreted IL-15 due to the unavailability of murine rIL-15.
Animal studies
Cytokine producers or wild-type (wt) cells ( . Statistical analysis was performed using a one-way analysis of variance and Scheffe's F test. For in vivo depletion of NK activities, nude mice were injected intraperitoneally (i.p.) with anti-asialo GM 1 antibody (Ab) (100 g/mouse, Wako, Osaka, Japan) 1 day before the inoculation of tumor cells. 34 Tumor cells were also injected i.p. into nude mice, and the survival days of the mice were assessed with the KaplanMeier method. Statistical analyses were performed by the log-rank test.
Flow cytometry
Cytokine producers or wt cells were incubated with fluorescein isothiocyanate (FITC)-conjugated mouse anti-HLA-A,B,C mAb (PharMingen) in the presence of 0.1% sodium azide. As a control, each cell population was reacted with isotypematched, FITC-conjugated mouse immunoglobulin G1 (IgG1) mAb. For analysis of the mice that received anti-asialo GM 1 Ab, spleen cells were stained with anti-asialo GM 1 Ab or with normal rabbit sera as a control on days 3 and 7. They were then incubated with FITC-conjugated goat anti-rabbit IgG Ab. The stained cells were analyzed with a FACScan (Becton Dickinson, Mountain View, Calif) and CellQuest software (Becton Dickinson).
Immunohistochemical analysis
Tumors were resected when they grew up to 5 mm in diameter and cryostat sections of 5 m in thickness were obtained. These sections were fixed in acetone/methanol (1:1) (for CD11b, CD54, CD90, CD106, or ␥␦ T-cell receptor (TCR) staining) or acetone (for CD31 staining), and endogenous peroxidase activity was blocked with 0.3% H 2 O 2 in methanol.
The sections were subsequently incubated with rat antiCD11b, rat anti-CD31, rat anti-CD90, rat anti-CD106, hamster anti-CD54, or hamster anti-␥␦ TCR Ab, which recognizes an invariable region of the ␥␦-chains of TCR (PharMingen). After reactions with biotinylated anti-rat IgG or biotinylated antihamster IgG Ab (PharMingen), the sections were stained with a Vectastain avidin-biotin complex kit and a diaminobenzidine substrate kit (Vector Laboratories, Burlingame, Calif).
RESULTS
In vitro analysis of wt and transduced AsPC-1 cells We obtained 25 and 22 clones as candidates for IL-12 and IL-15 producers, respectively. Of these, we chose a clone that secreted the largest amount of IL-12 (1292 pg/mL/1 ϫ 10 6 cells/48 hours) and a clone that secreted the largest amount of IL-15 for the following experiments. The expression levels of class I antigens of major histocompatibility complex of the transduced clones were not different from those of wt cells, and their in vitro proliferation rates remained the same as those for wt cells (data not shown).
Tumorigenicity of wt and transduced AsPC-1 cells in nude mice
To test whether antitumor effects can be produced by the expression of these cytokines, cytokine producers or wt cells were injected s.c. into nude mice (Fig 1) . The mice that received IL-12 or IL-15 producers developed tumors, but the average growth rate of the tumors was significantly retarded compared with that of wt tumors (P Ͻ .05). The growth retardation of the tumors of IL-12 producers was greater than that of the tumors of IL-15 producers.
Tumor cells were also injected i.p. Although all of the mice injected with wt cells died within 86 days, five of the eight mice that received IL-12 producers and six of the eight mice inoculated with IL-15 producers survived until the end of the observation period (P Ͻ 0.0001, Fig 2) .
Antitumor effect of cytokine producers in SCID or NK-depleted nude mice
To analyze the types of cells involved in the antitumor effect, cytokine producers or wt cells were injected s.c. into SCID mice (Fig 3) . Tumors of IL-12 producers showed significant growth retardation in comparison with those of wt cells (P Ͻ .05), as observed in the experiment using nude mice. The tumor growth of IL-15 producers was relatively suppressed but the growth retardation was statistically insignificant when compared with wt tumors (P ϭ .18). To examine whether NK cells possibly had a role in the antitumor effect caused by the cytokine producers, anti-asialo GM 1 Ab was administered i.p. into nude mice and the tumor cells were injected s.c. A complete depletion of asialo GM 1 -positive cells in the spleen cells of the Ab-treated mice was confirmed with cell surface staining with the Ab (Fig  4A) . The growth rate of the IL-12 producers was not affected by the administration of the Ab, but the rate of the IL-15 producers was greater in the Ab-treated mice than in nontreated mice (Fig 4B) .
Immunohistochemical staining
Tumors of cytokine producers and wt cells were analyzed immunohistochemically to determine the type of cells that migrated into the tumors. CD11b ϩ cells migrated into the tumors of the IL-12 and IL-15 producers, and even into the tumors of wt cells (Fig 5, A-C) . The numbers of CD11b ϩ cells were not different among the tumors. CD90 ϩ or ␥␦ TCR ϩ cells were scarcely found in any of these tumors (data not shown). The numbers of CD31 ϩ endothelial cells in neovascularization areas were not different between the tumors of IL-12 producers and those of wt cells (Fig 5, D and E 
Effect of simultaneous secretion of both IL-12 and IL-15
We tested the antitumor effect produced by the simultaneous secretion of IL-12 and IL-15 from tumor cells. Tumors derived from a mixture of both cytokine producers showed significantly retarded growth compared with those of wt cells and those from a mixture of IL-15-producers and wt cells (P Ͻ .01 and P Ͻ .05, respectively, on day 30, Fig 6A) . The growth retardation of tumors from the mixture of both cytokine producers was greater than that of tumors from a mixture of IL-12-producers and wt cells, without statistical significance (P ϭ .29 on day 30, Fig 6A) .
DISCUSSION
In the present study, we investigated whether IL-12 and IL-15, both of which participate in a Th1-type immune response, could produce antitumor effects on human pancreatic cancer cells. The results showed that localized secretion of either IL-12 or IL-15 could suppress the tumor growth even in an ␣␤ T-cell-deficient state and consequently prolong survival of the inoculated mice compared with that of control mice injected with wt cells (Figs 1 and 2) . We also examined the antitumor effects of the cytokine producers in SCID mice, which are deficient in ␥␦ T cells, B cells, and NK1 T cells as well as ␣␤ T cells, and in nude mice whose NK cells are eliminated with anti-asialo GM 1 Ab.
As for the IL-12-mediated antitumor effect, ␥␦ T cells, B cells, and NK cells are not essential based on the results using SCID mice (Fig 3) and NK cell-depleted nude mice (Fig 4B) . Immunohistochemical staining revealed that CD11b ϩ cells infiltrated into the tumors of IL-12 producers. This finding suggests that involvement of granulocytes and/or macrophages is required for the antitumor response. Yu et al 35 reported that IFN-␥, which was produced in response to IL-12, acted on CD11b ϩ cells and induced the expression of inducible nitric oxide synthase (iNOS); they also showed that the nitric oxide produced in turn exhibited a tumoricidal effect. 35 Therefore, we examined the expression of iNOS, a marker of activated macrophages, with the reverse transcription-based polymerase chain reaction method using RNA extracted from the tumors of IL-12 producers, IL-15 producers, and wt cells. The amounts of iNOS transcripts were not significantly different among the tumors (data not shown). Consequently, we presume that macrophages may not play a pivotal role in the antitumor effect. By comparing the tumor growth rate in nude mice with that in SCID mice, we judged that NK1 T cells were not involved in the IL-12-mediated antitumor effect. On the contrary, Cui et al 36 recently reported that NK1 T cells are essential for an IL-12-mediated rejection of tumors. Although recombinationdefective SCID mice are theoretically not able to generate NK1 T cells, we cannot exclude the possibility that unidentified functionally equivalent NK1 T type cells in SCID mice are responsible for the IL-12-mediated antitumor effect we observed.
In addition to the ability to augment cell-mediated immunity, IL-12 can inhibit tumor-induced angiogenesis. 18 We assessed the numbers of microvessels in the vicinity of s.c. tumors by immunohistochemical staining using anti-CD31 Ab. However, we could not find any marked differences in the number of CD31 ϩ endothelial cells between IL-12-producing and wt tumors (Fig 5, D  and E) . The expression of CD54 and CD106 on the endothelia of blood vessels at tumor sites was also increased by the administration of rIL-12, and this up-regulation is important for the recruitment of immunocompetent cells to produce an IL-12-mediated antitumor effect. 37 Immunohistochemical staining in the present study did not reveal a difference of expression in any of the tumors (data not shown). Taken together, these observations indicate that infiltrated CD11b ϩ granulocytes may play a certain role in the IL-12-mediated antitumor effect.
Growth inhibition of IL-15-producing tumors was less significant in SCID than in nude mice (Figs 1 and 3) . B cells, ␥␦ T cells, or NK-1 T cells, which are not present in SCID mice, can thereby be involved in the IL-15-mediated antitumor effect. A contribution of NK cells to the effect was also demonstrated using anti-asialo GM 1 -treated nude mice (Fig 4B) . The involvement of NK cells in the IL-15-mediated antitumor effect can be expected, because IL-15 is required for the differentiation, activation, and survival of NK cells. 26,38 -41 Because we showed that NK cells were not crucial in IL-2-mediated antitumor responses to AsPC-1 cells (our unpublished observations), the differential involvement of NK cells may be derived from the biological properties of both cytokines. Distinct cellular distributions of IL-2R and IL-15R 30 and possible differences of signaling via an ␣ subunit of respective receptors could distinguish the specificity of each cytokine. Because some of the mice that had rejected IL-15 producers showed growth retardation of rechallenged wt tumors (data not shown), the acquired immunity mediated by T cells is possibly induced. Although the infiltration of ␥␦ T cells in nude mice was not immunohistochemically demonstrated, ␥␦ T cells may play a role in the IL-15-mediated antitumor effect. In fact, IL-15 can enhance the expansion of ␥␦ T cells and maintain these cells in response to certain bacterial infections. 42 Recently Qin et al 43 confirmed that B cells inhibit the induction of T-cell-dependent tumor immunity and induce nonprotective immunity, although B cells can act as antigen-presenting cells. We speculate that B cells might not be involved in the antitumor immunity observed in this study. Nude mice possess NK1 T cells 44 and Ohteki et al 45 observed that NK1 T cells proliferate upon stimulation by IL-15. Although CD11b ϩ cells were detected in the tumors of IL-15 producers, an up-regulation of iNOS in the tumors was not observed (data not shown). Girard et al 46 showed that human neutrophils express the ␤-and ␥-chains of IL-2R and that IL-15 augments the phagocytic activity of neutrophils and makes them change morphologically to an activated form. Therefore, several types of effector cells can be involved in the IL-15-mediated antitumor effect. In an experiment using IL-15-producing murine colon cancer cells, an involvement of NK cells was not demonstrated, in contrast to the present study (our unpublished observations). We assume that the contribution of NK cells to IL-15-mediated antitumor responses may depend upon cell types.
The present study showed that IL-12 or IL-15 producers had not completely lost tumorigenicity. There are several reports concerning the synergistic effects of IL-12 and IL-15.
26, 42 We subsequently tested the effect of the simultaneous secretion of both IL-12 and IL-15 and observed that the tumor growth of the mixed population was significantly retarded compared with that of the population of IL-12 plus wt cells or IL-15 plus wt cells (Fig 6A) . However, the growth of the mixed population was not different from that of IL-12 or IL-15 producers alone (Fig 6B) . Synergistic antitumor effects of both cytokine producers were thereby not demonstrated. Further study is needed to explore a suitable ratio of IL-12 to IL-15 producers to produce a more beneficial effect. Because cytokines display pleiotropic functions through their networking, 47 it might be impossible to affect a whole immune system by increasing production of a single cytokine. The combinatory expression of other molecules such as costimulatory molecules is needed to achieve better antitumor effects.
